This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Cerivastatin - suspension of marketing and distribution

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Bayer has taken action to suspend the marketing and distribution of Lipobay (cerivastatin) in the UK and all other markets where gemfibrozil is available (1). This is because of concerns regarding the risk of rhabdomyolysis when cerivastatin is co-prescribed with gemfibrozil.

Bayer have recommended that patients who are currently receiving Lipobay should be transferred to alternative lipid lowering therapy when their next prescription is due. Also Bayer recommend that any patients who are receiving Lipobay in combination with gemfibrozil should be called for review and alternative lipid lowering treatment should be prescribed (1).

Reference:

  1. Bayer plc (9th August 2001). Letter re: Lipobay (cerivastatin) - suspension of marketing and distribution.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page